Sumgen Biotech

About Sumgen Biotech

Sumgen Biotech, legally registered as Hangzhou Sumgen Biotech Co., Ltd., is a biopharmaceutical company established in 2015, with a strategic focus on the development and commercialization of antibody-based therapeutics for oncology and autoimmune diseases. The company was founded by Dr. Ming Lu, who currently serves as the CEO. Dr. Lu holds a Ph.D. in Immunology and has a background in genetically engineered antibody research, which forms the scientific foundation of the company. Co-founders include Dr. Tan, who oversees public affairs and strategic planning; Dr. Ding, who manages early-stage discovery and intellectual property; and Dr. Miao, who leads CMC research and regulatory affairs.

The firm operates R&D centers in both Beijing and Hangzhou, alongside an antibody industrialization base in Hangzhou, to create an integrated workflow from antibody discovery to clinical development and manufacturing. Sumgen's business model is centered on the in-house development of a proprietary drug pipeline and engaging in strategic partnerships with established pharmaceutical corporations for co-development and commercialization. A key collaboration is with CSPC Pharmaceutical Group for the joint development of SG001. The company generates revenue through these partnerships, which include milestone payments and potential sales royalties. Sumgen has successfully raised capital through multiple financing rounds, including a Series B round of 220 million RMB in September 2020 and a Series B+ round of over 200 million RMB, to advance its clinical trials and expand its manufacturing capabilities.

Sumgen's product pipeline features several antibody drug candidates. Its leading asset, Enlonstobart (SG001), a PD-1 monoclonal antibody, received marketing approval in China in June 2024 for treating malignant tumors. Other significant clinical-stage candidates include SG301, a subcutaneously injected anti-CD38 antibody for systemic lupus erythematosus, and SG404, both of which have received IND approval in China and the US. The company has also developed multiple technology platforms, such as a mammalian cell display platform and bispecific antibody platforms known as BIMA and BITA, to fuel its drug discovery engine.